Cyclosporine A ameliorates ulcerative colitis by inhibiting cellular senescence, modulating the JAK2-STAT3/NF-κB signaling pathway, and regulating the gut microbiota-metabolite axis - PubMed
4 hours ago
- #ulcerative-colitis
- #cellular-senescence
- #microbiota-metabolite
- Cyclosporine A (CsA) alleviates ulcerative colitis (UC) by inhibiting cellular senescence.
- CsA modulates the JAK2-STAT3/NF-κB signaling pathway, reducing pro-inflammatory cytokines like IL-6, IL-1β, and TNF-α.
- CsA regulates the gut microbiota-metabolite axis, improving intestinal barrier function.
- Multi-omics analyses (network pharmacology, transcriptomics, metabolomics, metagenomics) support CsA's therapeutic mechanisms.
- Findings suggest CsA as a potential therapeutic for UC by targeting senescence and microbiota-metabolic regulation.